The late-stage failure of AstraZeneca's Wainua (eplontersen) in the Phase 3 CARDIO-TTRansform trial is a first-in-class setback for TTR gene-silencing therapies in ATTR-cardiomyopathy (ATTR-CM). While the antisense oligonucleotide (ASO) proved its mechanism by securing approval in polyneuropathy (ATTRv-PN) with an 81.7% TTR knockdown in the NEURO-TTRansform study, this efficacy did not translate to the larger, more lucrative cardiac indication. [1] The failure solidifies the market dominance of mechanistically distinct TTR stabilizers, namely Pfizer's tafamidis and BridgeBio’s recently-approved acoramidis, which have demonstrated survival benefits in ATTR-CM. [2][3] This outcome raises significant questions about the viability of the entire TTR-silencing class, including Alnylam’s vutrisiran (siRNA), in treating established cardiac amyloidosis. The CARDIO-TTRansform trial was designed to show benefit on top of standard of care, which could include TTR stabilizers, making the failure to demonstrate an additive effect particularly telling. No direct precedent for a successful TTR gene-silencer exists in ATTR-CM; eplontersen’s failure now sets a negative one. The core risk is that TTR synthesis inhibition alone is insufficient to address advanced cardiac amyloid burden, suggesting a fundamental biological barrier that may require different mechanisms like fibril removal
